

Specialty R&D Pipeline

Phase 2	Phase 3	Registration	Approved in 2017
Fremanezumab (anti CGRP) for Post-Traumatic Headache	Fremanezumab (anti CGRP) <i>Cluster Headache</i>	Fremanezumab (anti CGRP) <i>Chronic migraine</i>	Vantrela [®] ER <i>Pain (U.S.)</i>
Fasinumab ² <i>Chronic Lower Back Pain</i>	Fasinumab ² <i>Osteoarthritis pain</i>	Fremanezumab (anti CGRP) <i>Episodic migraine</i>	Austedo [®] <i>Huntington Disease (U.S.)</i>
Laquinimod <i>Multiple sclerosis (progressive forms)</i>	Austedo [®] (SD-809) ⁶ <i>Tourette Syndrome (U.S.)</i>	Azilect [®] ⁴ Parkinson's disease (Japan)	Austedo [®] <i>Tardive dyskinesia (U.S.)</i>
Laquinimod <i>Huntington disease</i>	Reslizumab SC ¹ <i>Asthma (Global)</i>	ProAir e-Respiclick E-connectivity (U.S.)	ArmonAir [®] RespiClick [®] <i>Asthma (U.S.)</i>
Pridopidine <i>Huntington disease</i>		CT-P10 ³ <i>Biosimilar (Rituxan[®] U.S.)</i>	AirDuo [®] RespiClick [®] <i>Asthma (U.S.)</i>
		CT-P6 ³ <i>Biosimilar (Herceptin[®] U.S.)</i>	QVAR [®] (beclomethasone dipropionate BAI) <i>Asthma (U.S.)</i>
		BENDEKA [®] ⁵ <i>CLL and NHL (Growth Markets)</i>	Reslizumab IV ¹ <i>Asthma (selective Growth Markets)</i>
		Trisonex [®] <i>for Acute Promyelocytic Leukemia (U.S.)</i>	

17 programs in phase 2 through Submission, 24 products in phase 1 or planned IND by 2019

- Migraine & Pain 6
- Neurology & neuropsychiatry 5
- Respiratory 2
- Biosimilars 2
- Other TA 2

Note: Pipeline is current as of November 2, 2017.

¹ Approved in the U.S under the trade name: CINQAIR[®] ²In partnership with Regeneron ³ In partnership with Celltrion

⁴ Submitted by Takeda ⁵ In partnership with Eagle Pharmaceuticals ⁶ In partnership with Nuvelution Pharma